Cite

HARVARD Citation

    Latif, F. et al. (2022). Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert review of anticancer therapy. 22 (2), pp. 229-235. [Online]. 
  
Back to record